Trial reportEuropean journal of nutrition2026
A multifaceted lifestyle program for weight loss in overweight adults: evidence from a randomised clinical trial.
Trial report in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeObesity and associated metabolic disorders represent a major global health challenge. The objective of this study was to determine the efficacy of a Multifaceted Lifestyle Program (MLP, combining dietary advice and supplementation with dietary fibre, probiotics and chromium) on weight, body composition and markers of metabolic health in overweight adults.
methodsFifty-seven overweight adults (BMI 25–29.9 kg/m2, aged 19–65 years) participated in an 8-week intervention trial, with 50 completing the study. Participants were randomised into three groups (A–C): A: placebo (rice powder; control); B: MLP + BioPB (an equal part blend of carrageenan, konjac and cellulose); and C: MLP + P (psyllium fibre). The primary outcome was changes in anthropometric and metabolic health indices at 4 and 8 weeks. The secondary outcome was the effect of the different fibres.
resultsAt week 4, participants receiving MLP + P and MLP + BioPB exhibited significant reductions (p < 0.001) in body weight (− 4.8 kg; and − 5.1 kg, respectively), BMI (− 1.7 kg/m2 and − 1.7 kg/m2, respectively), body fat mass (− 3.7 kg and − 4.2 kg) and visceral fat scores (− 1.9 and − 2.4). Some lean tissue mass loss was also evident. These changes were sustained for 4 weeks post-intervention. MLP + P and MLP + BioPB showed differing effects on blood lipids and inflammatory markers: reductions in cholesterol and LDL-cholesterol were greater and more persistent in the MLP + BioPB group, whereas the CRP levels (high CRP levels are linked to inflammation and metabolic disorders) were significantly reduced in the MLP + P group only. Significant improvements were also observed in the liver and kidney functions. No notable changes were observed in any parameters in the control group.
conclusionThe MLP, incorporating fibre supplementation, produced clinically significant improvements in body weight, BMI and body fat in overweight adults, offering a practical strategy for managing obesity. Importantly, the type of dietary fibre used had distinct metabolic effects, underscoring the need for tailored fibre interventions to optimise metabolic health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.